《生命科学》 2018, 30(5): 575-579

肝细胞癌靶向治疗最新研究进展

邱盛萍，黄承浩*

(厦门大学生命科学学院分子疫苗学和分子诊断学国家重点实验室，国家传染病诊断试剂与疫苗工程技术研究中心，厦门 361102)

摘　要：摘　要：近年来，随着肝细胞癌基础研究不断深入，分子靶向药物及免疫治疗药物的临床开发及应用为肝细胞癌的治疗带来了新的突破。肝细胞癌的靶向治疗药物具有较高的特异性，能够选择性地杀伤肿瘤细胞，尽可能减少对正常组织的损伤。目前，这些靶向治疗药物主要分为小分子靶向药物、肝细胞癌抗原特异性靶向药物和免疫检验点靶向药物3 类。现就肝细胞癌靶向治疗药物的最新研究进展作简要综述。

The latest research progress of targeted therapy for hepatocellular carcinoma

QIU Sheng-Ping， HUANG Cheng-Hao*

(State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics， National Institute of Diagnostics and Vaccine Development in Infectious Diseases， School of Life Sciences， Xiamen University， Xiamen 361102， China)

Abstract: Abstract: In recent years， with the deepening of basic research of hepatocellular carcinoma (HCC)， the clinical development and application of molecular targeted drugs and immunotherapeutic drugs have brought new breakthroughs in the treatment of hepatocellular carcinoma. Because of high specificity， targeted drugs can selectively kill tumor cells and as far as possibly reduce the damage to normal tissues. At present， targeted therapy drugs for HCC can be divided into three categories: small molecule targeted drugs， hepatocellular carcinoma antigen specific targeted drugs， and immune checkpoint targeted drugs. In this article， the latest progress of HCC targeted therapy was discussed.